Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation by Hirbe, Angela C. et al.
Oncotarget7403www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 7
Spatially- and temporally-controlled postnatal p53 knockdown 
cooperates with embryonic Schwann cell precursor Nf1 gene 
loss to promote malignant peripheral nerve sheath tumor 
formation
Angela C. Hirbe1, Sonika Dahiya2, Dinorah Friedmann-Morvinski3, Inder M. Verma3, 
D. Wade Clapp4 and David H. Gutmann5
1 Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
2 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
3 The Salk Institute of Biological Studies, Laboratory of Genetics, La Jolla, CA, USA
4 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
5 Department of Neurology, Washington University, St. Louis, MO, USA
Correspondence to: David H. Gutmann, email: gutmannd@neuro.wustl.edu
Keywords: Neurofibromatosis Type 1, MPNST, lentivirus, p53, mouse models
Received: October 26, 2015 Accepted: January 27, 2016 Published: February 07, 2016
AbstrAct
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive 
sarcomas that arise sporadically or in association with the Neurofibromatosis type 
1 (NF1) cancer predisposition syndrome. In individuals with NF1, MPNSTs are 
hypothesized to arise from Nf1-deficient Schwann cell precursor cells following the 
somatic acquisition of secondary cooperating genetic mutations (e.g., p53 loss). To 
model this sequential genetic cooperativity, we coupled somatic lentivirus-mediated 
p53 knockdown in the adult right sciatic nerve with embryonic Schwann cell precursor 
Nf1 gene inactivation in two different Nf1 conditional knockout mouse strains. Using 
this approach, ~60% of mice with Periostin-Cre-mediated Nf1 gene inactivation 
(Periostin-Cre; Nf1flox/flox mice) developed tumors classified as low-grade MPNSTs 
following p53 knockdown (mean, 6 months). Similarly, ~70% of Nf1+/- mice with 
GFAP-Cre-mediated Nf1 gene inactivation (GFAP-Cre; Nf1flox/null mice) developed low-
grade MPNSTs following p53 knockdown (mean, 3 months). In addition, wild-type and 
Nf1+/- mice with GFAP-Cre-mediated Nf1 loss develop MPNSTs following somatic p53 
knockout with different latencies, suggesting potential influences of Nf1+/- stromal 
cells in MPNST pathogenesis. Collectively, this new MPNST model system permits the 
analysis of somatically-acquired events as well as tumor microenvironment signals 
that potentially cooperate with Nf1 loss in the development and progression of this 
deadly malignancy.
INtrODUctION
MPNSTs are an aggressive subtype of soft-tissue 
sarcoma that develops in association with peripheral 
nerves or nerve roots. Composed of neoplastic 
Schwann cells, these malignancies are thought to arise 
from benign nerve sheath tumors, termed plexiform 
neurofibromas. Plexiform neurofibromas are frequently 
detected during early childhood, raising the possibility 
that they are congenital tumors that initiate during fetal 
or early postnatal life. While transformation of these 
plexiform neurofibromas in childhood is uncommon, the 
development of pain or motor weakness associated with 
a pre-existing plexiform neurofibroma in a teenager or 
young adult should prompt evaluation for a MPNST. In 
patients with these malignant tumors, overall survival is 
poor, and successful treatment options are limited. Even 
when surgery is employed in combination with radiation 
or chemotherapy, ~50% of individuals will experience 
local recurrence as well as distant metastases, and the 
majority will succumb to their cancer within 5 years [1-3]. 
MPNSTs occur most frequently in the setting of 
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the Neurofibromatosis 1 (NF1) tumor predisposition 
syndrome, affecting approximately 8-13% of people with 
NF1 [4]. Individuals with NF1 are born with a germline 
mutation in one copy of the NF1 gene, such that all 
cells in their bodies have one dysfunctional NF1 allele. 
However, tumorigenesis requires somatic loss of the other 
NF1 allele in the appropriate cell of origin. Consistent 
with a key role for the NF1 gene in both NF1-associated 
and sporadic MNPST pathogenesis, bi-allelic NF1 gene 
inactivation has been reported in approximately 60-90% 
of NF1-associated MPNSTs and 40-60% of sporadic 
cases [5, 6]. While loss of NF1 gene expression is 
required for MPNST development, it is not sufficient. As 
such, MPNST formation requires additional cooperating 
genetic events, the most frequent of which is mutational 
inactivation of the TP53 tumor suppressor gene, occurring 
in approximately 75% of cases [7-9].
In this regard, genetically-engineered mouse (GEM) 
lines with conditional Nf1 gene inactivation in Schwann 
cell precursors do not develop MPNSTs [10-14] unless 
coupled with concomitant Trp53 loss [15, 16], epidermal 
growth factor receptor (Egfr) amplification [7, 17], Pten 
loss [18], or Ink4a deletion [19, 20]. In each of these GEM 
strains, the cooperating genetic mutation was introduced 
simultaneously with Schwann cell precursor Nf1 gene 
inactivation throughout the body. While each of these 
models has been informative for understanding MPNST 
pathogenesis, they do not permit temporal (timing of the 
cooperating somatic genetic change) or spatial (specific 
nerve location) control over MPNST development. 
To generate a model in which temporal control of the 
transforming genetic alteration can be achieved in a single 
nerve location, we employed two GEM strains in which 
Cre-mediated Nf1 inactivation occurs in Schwann cell 
precursor cells during embryogenesis and p53 knockdown 
is somatically acquired at 6-8 weeks of age in cells 
within the right sciatic nerve. Using this approach, 60-
70% of mice develop sciatic nerve MPNSTs associated 
with focal neurological dysfunction. The coupling of 
somatic retroviral knockdown and embryonic Nf1 gene 
inactivation establishes an experimentally-manipulable 
platform to evaluate other cooperating genetic changes in 
MPNST pathogenesis as well as preclinical mouse strains 
in which clinical symptomatology can be used to monitor 
tumor progression.
rEsULts AND DIscUssION
Leveraging whole exome sequencing 
methodologies, a recent study from our laboratory 
revealed a temporal sequence of genetic changes in a 
single patient with progression of an NF1-associated 
plexiform neurofibroma to MPNST over a 14-year period. 
Analysis of these pathological specimens demonstrated an 
increasing proportion of cells with a somatic NF1 gene 
mutation (second hit) as the tumor progressed from a 
benign plexiform neurofibroma to a MPNST. In addition, 
loss of one copy of the TP53 gene was only detected at the 
MPNST stage [21]. These observations in a single patient 
support a model in which NF1 gene inactivation precedes 
TP53 mutation in the pathogenesis of NF1-associated 
MPNST.
To model this temporal sequence in mice, we 
leveraged two different GEM strains in which bi-allelic 
Nf1 gene inactivation occurred in Schwann cell precursors 
during embryonic development. For these experiments, 
Nf1flox/flox mice were intercrossed with either Periostin-Cre 
[22, 23] or GFAP-Cre [24] mice to eliminate Nf1 protein 
(neurofibromin) expression in Schwann cell precursors. 
We first sought to generate mice with a germline null 
Nf1 gene mutation and a conditional Nf1 allele; however, 
the majority of Periostin-Cre; Nf1flox/null mice did not 
survive to weaning age (~3-4 weeks), as previously 
reported by others [23]. As such, Periostin-Cre; Nf1flox/flox 
mice and GFAP-Cre; Nf1flox/null mice, were used for these 
experiments. Importantly, neither strain develops MPNSTs 
without the introduction of additional genetic alterations 
(e.g., somatic p53 knockdown). 
In the Periostin-Cre model, promoter activity is 
detected as early as embryonic day 10 (E10) within 
post-migratory Schwann cell progenitor cells. Based on 
published reporter activity studies, recombination occurs 
in the enteric nervous system, peripheral nervous system 
(including Schwann cells), and within a subpopulation of 
cardiac outflow tract mesenchymal cells [22]. As expected, 
intercrossing Periostin-Cre mice with a Rosa-GREEN 
reporter strain [25] revealed green fluorescent protein 
(GFP) expression in sciatic nerves (Figure 1a). Similarly, 
in the GFAP-Cre model, where promoter activity has been 
reported as early as E13.5 in the brain [24], we observed 
robust GFP expression in the sciatic nerves of adult GFAP-
Cre mice following intercrossing with Rosa-GREEN 
reporter mice (Figure 1a).
To determine whether Cre-mediated excision might 
also occur in the hematopoietic cells that populate the 
tumor microenvironment [12, 26-28] (e.g., mast cells and 
macrophages), both Cre driver lines were intercrossed 
with Rosa-GREEN reporter mice [25]. Whereas GFP 
expression was observed within the adult sciatic nerve, 
there was no GFP labeling within the bone marrow (Figure 
1a). The lack of GFP expression in the bone parenchyma 
demonstrates that Cre-mediated excision is largely limited 
to the Schwann cell precursors within the sciatic nerve, 
rather than infiltrating bone marrow-derived stromal cells 
in the tumor microenvironment. 
Western blot analysis of the sciatic nerves 
of Periostin-Cre; Nf1flox/flox mice revealed loss of 
neurofibromin expression, but intact p53 expression 
(Figure 1b). The absence of neurofibromin expression 
demonstrates that early Nf1 gene inactivation in Schwann 
cell precursors occurs prior to the induction of shRNA 
retrovirus-mediated p53 knockdown. Similar to Periostin-
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Cre; Nf1flox/flox mice, no neurofibromin expression was 
detected in the sciatic nerves of GFAP-Cre; Nf1flox/null mice 
by western blot (Figure 1b). 
Next, to introduce p53 knockdown specifically in 
cells within the sciatic nerve, we leveraged a lentiviral 
approach in which Nf1 and Trp53 knockdown occurs 
following p53 shRNA virus injection (Figure 2a). This 
construct has previously been employed to reduce Nf1 and 
Trp53 gene expression in the brain in vitro and in vivo, 
resulting in high-grade gliomas [29]. In this regard, we 
observed 40% and 70% reductions in neurofibromin and 
p53 expression, respectively, in NIH-3T3 cells 96 hours 
post-lentiviral infection in vitro (Figure 2b). The choice 
to employ a lentivirus containing shRNAs targeting both 
the Nf1 and Trp53 genes reflected a lack of reproducible 
knockdown (KD) when the identical Trp53 shRNA was 
employed alone (data not shown). Importantly, since Nf1 
expression has already been silenced in GFAP-Cre; Nf1flox/
null, GFAP-Cre; Nf1flox/flox, and Periostin-Cre; Nf1flox/flox 
mice, the effects of shRNA Nf1 KD on the preneoplastic 
Schwann cell component should be negligible. 
For all MPNST induction experiments, adult sciatic 
nerves were surgically isolated and injected with p53 
shRNA lentivirus when the mice reached 6-8 weeks of 
age. Mice were then monitored by serial examination until 
they demonstrated neurological abnormalities (e.g., right 
leg weakness), at which time they were euthanized for 
gross pathological and histological analyses (Figure 2c). 
Initial experiments used mice in which 
neurofibromin expression was ablated in periostin-
expressing cells, including Schwann cell precursors within 
the peripheral nerves (Periostin-Cre; Nf1flox/flox mice), 
consistent with previous lineage tracing studies [30]. 
While the precise cell of origin is not known in this model, 
Cre-driven reporter expression has been observed in brain 
lipid binding protein (BLBP)-immunoreactive cells, which 
represent Schwann cell precursors or immature Schwann 
cells [30]. To induce MPNSTs, pTomo-shNf1;shp53 
lentivirus or vehicle was injected into the right sciatic 
nerves of 6-8 week old Periostin-Cre; Nf1flox/flox mice, 
resulting in GFP expression following Cre-mediated 
recombination (Supplemental Figure 1a). Following the 
Figure 1: Murine MPNst model system employed. a. Representative images of sciatic nerves and femurs (bone) from GFAP-Cre 
(FVB-Tg(GFAP-cre)25Mes/J) and Periostin-Cre mice crossed to Rosa-Green reporter mice. Green fluorescent protein (GFP)-positive cells 
were observed in the sciatic nerve and bone periosteum (white arrows), but not in the hematopoietic cells within the bone parenchyma. 
Scale bar, 50µm. b. Western blotting reveals complete loss of neurofibromin expression and intact p53 expression in Periostin-Cre; Nf1flox/
flox and GFAP-Cre; Nf1flox/null sciatic nerves compared to intact neurofibromin and p53 expression in the wild-type sciatic nerve. 
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Figure 2: Lentiviral introduction of ptomo-shNf1;shp53 into the sciatic nerve. a. Schematic of the pTomo-shNf1;shp53 
lentivirus construct used in these studies [29]. b. Western blotting demonstrates a 40% reduction in neurofibromin expression and a 70% 
reduction in p53 expression 96 hours after pTomo-shNf1;shp53 lentiviral infection of NIH-3T3 cells. c. Schematic of study design. d. 
Western blotting reveals complete loss of neurofibromin expression coupled with a 60% reduction in p53 expression within the sciatic 
nerves of Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus relative to uninjected control nerves. e. Western blotting 
reveals complete loss of neurofibromin expression coupled with an 80% reduction in p53 expression within the sciatic nerves of GFAP-Cre; 
Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus relative to uninjected control nerves.
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injection of this lentivirus into the right sciatic nerves 
of 6-8 week old mice, the pre-existing complete loss 
of neurofibromin expression in these nerves was now 
accompanied by a 60% reduction in p53 protein expression 
within the tumors (Figure 2d). With an average latency of 
183 days post-injection (Table 1), ~60% of the pTomo-
shNf1;shp53 lentivirus-injected Periostin-Cre; Nf1flox/flox 
mice exhibited paresis of the affected leg, as evidenced 
by pronounced right-sided lower extremity limping. At 
this time, these mice were euthanized and their sciatic 
nerves evaluated for the presence of a malignant tumor. In 
10/18 of these mice, grossly-appearing mass lesions were 
appreciated in the nerves of lentiviral-injected animals, but 
not in the vehicle-injected controls (Figure 3a). 
Neuropathological analyses of the resulting tumors 
revealed striking hypercellularity, mild to moderate 
nuclear pleiomorphism, reduced S100β immunopositivity, 
increased Ki67 labeling (Figure 3b), infiltration of 
adjacent fibroadipose tissue, and mitotic figures 
(Supplemental Figure 1b), as seen in their human low-
grade MPNST counterparts. Additionally, these murine 
MPNSTs retained basement membrane staining (Collagen 
4A; Col4a immunoreactivity) and demonstrated mast cell 
infiltration visualized by tryptase staining, as reported in 
other murine MPNST-like tumors [31] (Figure 3b). Based 
on the observed increased cellularity, nuclear atypia, and 
mitotic activity, these lesions are most accurately classified 
as low-grade MPNST, as suggested by the Comparative 
Pathology of Nerve Sheath Tumors in Mouse Models 
and Humans Committee Consensus Report [32]. The 
remaining 8 mice exhibited hyperplasia only, similar to 
some of the vehicle-injected mice.
The development of MPNSTs in mice without 
complete loss of p53 expression (Figure 2d) suggests that 
bi-allelic (complete) inactivation of the Trp53 gene might 
not be necessary for malignant transformation. While 
we cannot exclude the acquisition of additional genetic 
changes that effectively abrogate p53 signaling, previous 
reports in both mouse models and human pathological 
MPNST specimens have likewise support the concept 
that TP53 haploinsufficiency may be sufficient for 
MPNST formation [7, 9]. Similarly, our recent whole 
exome sequencing analysis of a single patient with NF1-
related plexiform neurofibroma malignant transformation 
revealed only heterozygous TP53 loss [21]. 
The development of MPNSTs in Periostin-Cre; 
Nf1flox/flox mice raises the intriguing possibility that 
malignant transformation does not require heterozygous 
Nf1 loss in cells within the tumor microenvironment. 
While previous studies from one of our laboratories 
(D.W.C.) have clearly demonstrated a critical role for 
infiltrating Nf1+/- stromal cells in benign murine plexiform 
neurofibroma formation and growth [12, 27, 28], the 
apparent stromal independence in MPNST pathogenesis 
could reflect differences between low-grade tumor growth 
requirements and those operative in malignant cancers. In 
this respect, similar differences have also been reported 
for murine Nf1 brain tumors: Nf1+/- stromal cells are 
required for low-grade murine optic glioma formation 
and continued growth in vivo [33-35], but high-grade 
glioblastoma development can occur following Nf1 and 
p53 inactivation in nestin+ neural stem cells alone in vivo 
[36]. 
Since the early lethality (pre-weaning) observed 
in Nf1+/- mice with periostin-Cre-mediated Nf1 gene 
inactivation precluded an examination of the contribution 
of the Nf1+/- tumor microenvironment to MPNST biology, 
we sought to reduce the latency of MPNST development 
by coupling somatic retrovirus-mediated p53 knockdown 
and embryonic Schwann cell precursor Nf1 gene 
table 1: MPNst development in Nf1 mutant mice following p53 knockdown
Mouse genotype (injection) Hyperplasia MPNst MPNst latency, mean days (range)
Periostin-Cre; Nf1flox/flox (vehicle) 2/11 0/11 No tumors: 83-304d*
Periostin-Cre; Nf1flox/flox (pTomo-shNf1;shp53) 8/18 10/18 183d (144-278d)
GFAP-Cre; Nf1flox/null (vehicle) 2/6 0/6 No tumors: 49-217d*
GFAP-Cre; Nf1flox/null (pTomo-shNf1;shp53) 3/11 8/11 91d (25-211d)
GFAP-Cre; Nf1flox/flox (vehicle) 0/4 0/4 No tumors:129-153d* 
GFAP-Cre; Nf1flox/flox (pTomo-shNf1;shp53) 2/5 3/5 176d (117-298d)
Wild-type (pTomo-shNf1;shp53) 0/4 0/4 No tumors: 182-365d#
Nf1+/- (pTomo-shNf1;shp53) 0/4 0/4 No tumors: 182-365d#
*Vehicle mice were euthanized and analyzed at time points equivalent to those when p53 shRNA-injected mice were 
euthanized or at a time when they became ill due to non-tumor-related issues (rectal prolapse or hydrocephalus). The details 
are provided below:
Vehicle-injected GFAP-Cre; Nf1flox/null mice: 2 mice at 49 days, 2 mice at 154 days and 2 mice at 217 days.
Vehicle-injected Periostin-Cre; Nf1flox/flox mice: 1 mouse at 83 days, 3 mice at 144 days, 2 mice at 154 days, 2 mice at 230 days, 
2 mice at 259 days, and 1 mouse at 304 days.
Vehicle-injected GFAP-Cre; Nf1flox/flox mice: 2 mice at 129 days, 1 mouse at 138 days, and 1 mouse at 158 days.
Wild-type and Nf1+/- mice:  2 mice at 183 days and 2 mice at 365 days for each group.
#Wild-type and Nf1+/- mice were euthanized and analyzed at 6 month or 12 month time points, as no mice developed 
symptoms or non-tumor-related issues.
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Figure 3: MPNst development in mice with embryonic schwann cell precursor Nf1 loss and postnatal somatic Trp53 
reduction. a. Gross images of the sciatic nerves from Periostin-Cre; Nf1flox/flox mice injected with vehicle or pTomo-shNf1;shp53 virus. 
Low-grade MPNSTs were only observed in the sciatic nerves of Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus. Scale 
bar, 1000µm. b. Sciatic nerve sections from Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus demonstrate increased 
cellularity, nuclear pleiomorphism, and mitotic figures, consistent with low-grade MPNST (H&E). Induced MPNSTs exhibit reduced S100 
β-staining, increased Ki67 labeling, increased mast cell infiltration (tryptase staining), and collagen-4A (Col4A) basement membrane 
immunoreactivity. Scale bar, 40µm.
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Figure 4: MPNst formation is accelerated in Nf1+/- mice harboring embryonic Nf1 loss and somatic Trp53 reduction. 
a. Gross images of the sciatic nerves from GFAP-Cre; Nf1flox/null mice injected with vehicle or pTomo-shNf1;shp53 virus. Low-grade 
MPNSTs were only observed in the sciatic nerves of GFAP-Cre; Nf1flox/null mice injected with pTomo-shNf1;shp53 virus. Scale bar, 1000µm. 
b. Sciatic nerve sections from GFAP-Cre; Nf1flox/null mice injected with pTomo-shNf1;shp53 virus demonstrate increased cellularity and 
nuclear pleiomorphism, consistent with low-grade MPNST (H&E). Induced MPNSTs exhibit reduced S100 β-staining, increased Ki67 
labeling, increased mast cell infiltration (tryptase staining), and collagen-4A (Col4A) basement membrane immunoreactivity. Scale bar, 
40µm.
Oncotarget7410www.impactjournals.com/oncotarget
inactivation in the setting of an Nf1+/- microenvironment. 
For these experiments, we employed GFAP-Cre mice [24], 
in which Cre-mediated recombination occurs in the sciatic 
nerve (Figure 1a). In contrast to the Periostin-Cre; Nf1flox/null 
mice, the majority of which die by 4 weeks of life, Nf1flox/
null; GFAP-Cre mice are viable into adulthood. Similar to 
the experiments performed with the Periostin-Cre; Nf1flox/
flox mice, pTomo-shNf1;shp53 lentivirus or vehicle was 
injected into the sciatic nerves of 6-8 week old GFAP-Cre; 
Nf1flox/null mice. Following the injection of this lentivirus 
into the right sciatic nerves of 6-8 week old mice, the pre-
existing complete loss of neurofibromin expression in 
these nerves was now accompanied by an 80% reduction 
in p53 protein expression within the tumors (Figure 2e). 
While none of the vehicle-injected mice exhibited any 
neurological deficits, eight of eleven GFAP-Cre; Nf1flox/
null mice injected with pTomo-shNf1;shp53 lentivirus 
exhibited right leg weakness. Following euthanasia, gross 
morphological features of MPNST were observed (Figure 
4a). As observed with the pTomo-shNf1;shp53 lentivirus-
injected Periostin-Cre; Nf1flox/flox mice, MPNSTs in the 
GFAP-Cre; Nf1flox/null mice with somatic p53 knockdown 
exhibited striking hypercellularity, mild to moderate 
nuclear pleiomorphism, reduced S100β immunoreactivity, 
increased Ki67 labeling, mast cell infiltrates (Tryptase 
staining), infiltration of adjacent fibroadipose tissue, and 
Col4A immunoreactivity (Figure 3b). However, in contrast 
to pTomo-shNf1;shp53 lentivirus-injected Periostin-Cre; 
Nf1flox/flox mice, the average time to MPNST formation was 
only ~90 days as opposed to ~183 days. 
It is possible that the shortened MPNST latency 
observed in injected GFAP-Cre; Nf1flox/null mice reflected 
growth-promoting contributions from the heterozygous 
tumor microenvironment. Support for this idea derives 
from early findings in GFAP-Cre; Nf1flox/flox mice (harboring 
wild-type stromal cells) injected with pTomo-shNf1;shp53 
lentivirus. In this respect, the 3 mice that developed 
MPNSTs exhibited longer latencies than observed in 
GFAP-Cre; Nf1flox/null mice (average of 176 days, Table 
1). However, in striking contrast, 50% of the GFAP-Cre; 
Nf1flox/null mice injected with pTomo-shNf1;shp53 lentivirus 
had developed a limp and exhibited low-grade MPNST 
on pathological examination by 50 days post-injection. 
Coupled with the results obtained using Periostin-Cre; 
Nf1flox/flox mice, it is most likely that cells in the Nf1+/- 
tumor microenvironment provide additional growth 
factors or chemokines (e.g., CXCL12 [37]) that accelerate 
the growth of the newly-formed MPNST, leading to a 
reduced time to clinical symptomatology.
Since the lentivirus employed contained shRNAs 
that targeted both the Trp53 and Nf1 genes, we next 
sought to determine whether Nf1 shRNA-mediated 
KD was sufficient to generate MPNSTs in wild-type or 
Nf1+/- mice. Following injection of pTomo-shNf1;shp53 
lentivirus at 6 weeks of age, mice were examined 6 
months or 12 months later. No mice developed a limp 
and no tumors were appreciated on gross or histologic 
examination (Table 1). These findings lend further 
support to the hypothesis that loss of Nf1 gene expression 
in embryonic Schwann cell precursors is required for 
plexiform neurofibroma development and subsequent 
MPNST formation, as previously demonstrated by others 
[38-40]
The high frequency of MPNSTs in individuals with 
NF1 coupled with genetic analyses of human MPNSTs 
argues that NF1 loss is an obligate genetic event in MPNST 
development. Moreover, the fact that bi-allelic inactivation 
of the NF1 gene is observed in most NF1-associated [5, 
6, 41] and sporadic [42] MNPSTs supports a critical role 
for this tumor suppressor gene in MPNST pathogenesis. 
While neurofibromin loss in cells of the Schwann cell 
lineage is required for MPNST formation, it is clearly 
not sufficient. This lack of sufficiency is nicely illustrated 
in Nf1 GEM strains, where mice with conditional Nf1 
gene inactivation in Schwann cell precursors alone also 
do not develop MPNSTs [10-14], including the GFAP-
Cre; Nf1flox/null and Periostin-Cre; Nf1flox/flox mouse strains 
used in the current study. However, the co-existence of 
other cooperating genetic events in combination with Nf1 
loss does result in MPNST formation (summarized in 
Supplemental Table 1). In most of these mouse models, 
complex intercrosses of transgenic and conditional 
knockout strains are required, and there is no control over 
the timing of the acquired somatic genetic event or the 
location in which the malignancy will arise [7, 15-20, 
43-45]. Using a combination of conditional knockout 
mice and lentivirus-mediated somatic p53 inactivation, 
we describe an efficient platform for the generation of 
MPNSTs. As such, this model is ideally suited to define 
the biological importance of somatically-acquired 
cooperating genetic events to MPNST pathogenesis, 
thus allowing investigators to compare the effects of 
known somatic genetic alterations (e.g., p53 versus p16 
inactivation) or those identified in large-scale genomic 
discovery efforts [46]. In addition, this experimental 
system provides both spatial and temporal control. Future 
uses of this platform provide opportunities to determine 
the impact of introducing cooperating genetic mutations as 
a function of mouse age or in different peripheral nerves. 
Moreover, since somatic p53 knockdown is directed to 
the sciatic nerve, these mice develop a neurologic deficit 
(limp), similar to some patients with MPNSTs. The ability 
to monitor clinical signs will be important if these models 
are employed for preclinical studies. 
In summary, the implementation of this 
experimental MPNST model system has allowed us to 
make two important observations. First, we demonstrate 
that somatic reduction, but not absence, of Trp53 
expression following Nf1 gene inactivation is sufficient for 
MPNST formation. Second, we demonstrate that MPNST 
formation can occur in the absence of a microenvironment 
composed of cells heterozygous for a germline Nf1 gene 
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mutation. Future studies employing this platform may 
facilitate more rapid analyses of the contributions of other 
cooperating events to MPNST pathogenesis, the role of 
the tumor microenvironment in MPNST growth, and the 
development of radiologic and molecular biomarkers of 
malignant transformation.
MAtErIALs AND MEtHODs
Mice
GFAP-Cre (FVB-Tg(GFAP-cre)25Mes/J) and Rosa-
Green reporter mice were purchased from the Jackson 
Laboratories [24, 25]. Periostin-Cre [22] and Nf1flox/
flox [47] mice have previously been described. All mice 
were maintained on a C57Bl/6 background and used in 
accordance with approved animal studies protocols at the 
Washington University School of Medicine. 
Lentivirus generation
The pTomo-shNf1;shp53 lentivirus construct used 
has been previously described [29]. Viral particles were 
produced by the Viral Vectors Core Facility of the Hope 
Center for Neurological Diseases at the Washington 
University School of Medicine.
sciatic nerve injections
The right flanks of 6-8 week old mice were shaved 
and prepped with betadine. The right sciatic nerves were 
surgically isolated while mice were under anesthesia. 
10μl of pTomo-shNf1;shp53 lentivirus (5x106 IU) or 10μl 
vehicle was injected into the right sciatic nerves of mice 
using a10μl Hamilton syringe equipped with a 33-gauge 
needle. The surgical incision was closed with Vetbond and 
sutured. Mice were followed and examined three times per 
week until right-sided limping was observed. At this time, 
mice were euthanized with carbon dioxide and the sciatic 
nerves isolated for gross and histologic analysis.
tissue preparation
For eight-week-old GFAP-Cre; Rosa Green and 
Periostin-Cre; Rosa Green mouse nerves and bones 
were Formalin-fixed and paraffin-embedded. 5 micron-
thick sections were generated for analysis. Tissues 
were subsequently dehydrated and coverslipped with 
Vectashield mounting media containing DAPI (Vector 
Laboratories). 
Immunohistochemistry
Nerves were processed as described above 
using primary (Supplemental Table 2) and horseradish 
peroxidase-conjugated secondary antibodies (Vector 
Laboratories, Burlingame, CA, USA) in combination with 
Vectastain Elite ABC development. 
Microscopy
For eight-week-old GFAP-Cre; Rosa Green and 
Periostin-Cre; Rosa Green mouse nerves and bones, 
images were acquired at 100x magnification on a 
Nikon Eclipse TE300 fluorescence inverted microscope 
equipped with an optical camera (Leica DFC 3000G) 
and analyzed using Leica Application Suite Advanced 
Fluorescence 3.20.9652. Seven day post-injection images 
were acquired at 200x magnification on a Nikon Eclipse 
TE300 fluorescence inverted microscope equipped with an 
optical camera (Leica DFC 3000G). Images from tumor 
bearing mice were acquired at 400x magnification using 
an Olympus BX51 camera.
Western blotting
Cell pellets, sciatic nerves, or tumors dissected 
from sciatic nerves were lysed in buffer containing 1% 
NP-40 (nonylphenoxypolyethoxylethanol) supplemented 
with protease inhibitors. Western blotting was performed 
as previously described [48]. Antibodies used included 
neurofibromin (Santa Cruz Biotechnology; dilution 1:100), 
p53 (Cell Signaling; dilution 1:1000), and α-tubulin 
(Sigma; dilution 1:10000). Densitometry was measured 
using Life Science Software from UVP VisionWorks LS 
Version 8.1.1 Image Acquisition and Analysis Software 
system. α-tubulin serves as an internal protein loading 
control. 
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